Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871791 · ClinicalTrials.gov registry record · Phase 1
Palbociclib With Everolimus + Exemestane In BC
A Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02871791 is a Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 41 participants, below the 156-participant average among 3 other Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02871791, a Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: * Palbociclib * Everolimus * Exemestane
Conditions Studied
Interventions
- DRUG Exemestane
- DRUG Everolimus
- DRUG Palbociclib
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2021-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871791
The ClinicalTrials.gov registry entry for NCT02871791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 3 other Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials with a reported enrollment target (74% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Epidermal Growth Factor 2 Negative Carcinoma of Breast appearing as the primary indexed condition, and to 3 interventions - of which Exemestane is the first listed.
NCT02871791 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02871791 about?
NCT02871791 is a clinical study titled "Palbociclib With Everolimus + Exemestane In BC". This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: * ...
What is the current status of trial NCT02871791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-08-24. Estimated completion is 2021-09.
What conditions does trial NCT02871791 study?
This clinical trial studies the following conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer.
What interventions are being tested in trial NCT02871791?
The interventions under investigation include: Exemestane (DRUG), Everolimus (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02871791?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02871791 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
All registered trials for this condition
Hormone Receptor (HR)-Positive Breast Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.